Effects of Fermented Milk Containing Lacticaseibacillus paracasei Strain Shirota on Constipation in Patients with Depression: A Randomized, Double-Blind, Placebo-Controlled Trial
- 2021-06-29
- Nutrients 13(7)
- Xiaomei Zhang
- Shanbin Chen
- Ming Zhang
- F. Ren
- Yimei Ren
- Yixuan Li
- Ning Liu
- Yan Zhang
- Qi Zhang
- Ran Wang
- PubMed: 34209804
- DOI: 10.3390/nu13072238
Abstract
Probiotics have been shown to benefit patients with constipation and depression, but whether they specifically alleviate constipation in patients with depression remains unclear. The aim of this study was to investigate the effect of Lacticaseibacillus paracasei strain Shirota (LcS), formerly Lactobacillus casei strain Shirota, on constipation in patients with depression with specific etiology and gut microbiota and on depressive regimens. Eighty-two patients with constipation were recruited. The subjects consumed 100 mL of a LcS beverage (108 CFU/mL) or placebo every day for 9 weeks. After ingesting beverages for this period, we observed no significant differences in the total patient constipation-symptom (PAC-SYM) scores in the LcS group when compared with the placebo group. However, symptoms/scores in item 7 (rectal tearing or bleeding after a bowel movement) and items 8-12 (stool symptom subscale) were more alleviated in the LcS group than in the placebo group. The Beck Depression Index (BDI) and Hamilton Depression Rating Scale (HAMD) scores were all significantly decreased, and the degree of depression was significantly improved in both the placebo and LcS groups (p < 0.05), but there was no significant difference between the groups. The LcS intervention increased the beneficial Adlercreutzia, Megasphaera and Veillonella levels and decreased the bacterial levels related to mental illness, such as Rikenellaceae_RC9_gut_group, Sutterella and Oscillibacter. Additionally, the interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) levels were significantly decreased in both the placebo and LcS groups (p < 0.05). In particular, the IL-6 levels were significantly lower in the LcS group than the placebo group after the ingestion period (p < 0.05). In conclusion, the daily consumption of LcS for 9 weeks appeared to relieve constipation and improve the potentially depressive symptoms in patients with depression and significantly decrease the IL-6 levels. In addition, the LcS supplementation also appeared to regulate the intestinal microbiota related to mental illness.
Keywords: Lacticaseibacillus paracasei strain Shirota (LcS); constipation; depression.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lacticaseibacillus casei | Alleviated Rectal Bleeding | Beneficial | Small |
Lacticaseibacillus casei | Improved Depressive Symptoms | Neutral | Moderate |
Lacticaseibacillus casei | Improved Stool Symptoms | Beneficial | Small |
Lacticaseibacillus casei | Increased Beneficial Gut Microbiota | Beneficial | Moderate |
Lacticaseibacillus casei | Reduced Interleukin-6 Levels | Beneficial | Moderate |
Lacticaseibacillus casei | Regulated Inflammatory Markers | Beneficial | Small |
Lacticaseibacillus paracasei Lpc-37 | Improved Stool Symptoms | Beneficial | Small |
Lacticaseibacillus paracasei Lpc-37 | Reduced Gut Bacteria Associated with Mental Illness | Beneficial | Moderate |
Lacticaseibacillus paracasei Lpc-37 | Reduced Interleukin-6 Levels | Beneficial | Moderate |
Lacticaseibacillus paracasei Lpc-37 | Relief from Rectal Tearing or Bleeding After Bowel Movement | Beneficial | Moderate |